DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/rjng2f/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Alcobra Ltd
- Amarantus Bioscience Holdings, Inc.
- Arbor Pharmaceuticals, LLC.
- Cerecor Inc.
- Collegium Pharmaceutical, Inc.
- Curemark, LLC
- DURECT Corporation
- Eli Lilly and Company
- H. Lundbeck A/S
- Hisamitsu Pharmaceutical Co., Inc.
- Integrative Research Laboratories Sweden AB
- Intra-Cellular Therapies, Inc.
- KemPharm, Inc.
- Merck & Co., Inc.
- Mnemosyne Pharmaceuticals, Inc.
- Neos Therapeutics, Inc.
- NeuroDerm Ltd.
- Otsuka Holdings Co., Ltd.
- P2D Bioscience
- Polleo Pharma Limited
- Reviva Pharmaceuticals Inc.
- Samyang Biopharmaceuticals Corporation
- Shire Plc
- Signature Therapeutics, Inc
- Sunovion Pharmaceuticals Inc.
- Supernus Pharmaceuticals, Inc.
- Taisho Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical Company Limited
- Tris Pharma, Inc.
- Vernalis Plc
For more information visit http://www.researchandmarkets.com/research/rjng2f/attention_deficit
